<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425071</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 41558915900000068</org_study_id>
    <nct_id>NCT03425071</nct_id>
  </id_info>
  <brief_title>Monitoring Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood Lymphocytes of Kidney Transplant Recipients</brief_title>
  <official_title>Monitoring Intracellular Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood T CD4+ and B CD19+ Lymphocytes of Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria da Luz Fernandes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paschoalina Romano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Persio de Almeida Rezende Ebner</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nairo Massakazu Sumita</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Veronica Porto Carreiro de Vasconcelos Coelho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fabiana Agena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elias David Neto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nelson Zocoler Galante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic drug monitoring (TDM) of immunosuppressive drugs is used to improve the
      immunosuppressive effect while minimizing the toxicity related to exposition to high serum
      levels. Although TDM is widely used in clinical practice, a significant number of kidney
      transplant recipients have acute allograft rejection in the first year after transplantation.
      To improve the use of immunosuppressive drugs, new approaches of TDM have been developed.
      Monitoring drug concentrations at lymphocytes of peripheral blood is considering promising
      because it indicates the availability of the drug directly in the target sites of
      immunosuppression. The present study intends to establish the concentration profile of
      tacrolimus in the peripheral blood in parallel with the concentration profile inside T and B
      lymphocytes of peripheral blood of kidney transplant recipients, and correlates them with the
      expected pharmacological effects. The pharmacological effects of tacrolimus in calcineurin
      dependent and calcineurin independent (mitogen-activated protein kinase (MAPK) dependent)
      activation pathways will be assessed by measuring activated nuclear factor of activated T
      cells (NFAT) and p38, respectively, by flow cytometry. The expression of interleukin (IL) - 2
      and IL-10 by T and B lymphocytes, respectively, will be also used to monitoring the
      pharmacodynamic effects of tacrolimus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between blood and intracellular levels of tacrolimus</measure>
    <time_frame>From 1 up to 5 months post transplantation</time_frame>
    <description>The concentration of tacrolimus will be determined in the whole blood, in T CD4+ cell suspension and in B CD19+ cell suspension prepared from one blood sample per patient subject. The correlations among concentrations of tacrolimus in the 3 different cell matrices will be established.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation among intracellular levels of tacrolimus and its pharmacological effects</measure>
    <time_frame>From 1 up to 5 months post transplantation</time_frame>
    <description>The pharmacological effects of tacrolimus will be measured as the inhibition of the nuclear translocation of NFAT transcription factor, the phosphorylation state of p38 MAP kinase and the production of interleukin 2 and 10 by flow cytometry.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Rejection</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in &quot;in vitro&quot; experiments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>kidney transplant (KTx) months 1-2</arm_group_label>
    <description>Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in &quot;ex vivo&quot; experiments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KTx months 4-5</arm_group_label>
    <description>Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in &quot;ex vivo&quot; experiments.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include kidney transplant recipients followed at Hospital das Clínicas da
        Faculdade de Medicina da USP.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients with a well functioning graft (serum creatinine ≤ 2,0
             mg/dL at inclusion)

          -  Must be on tacrolimus therapy

          -  Must be on short term follow up time (1 to 5 months) after surgery

        Exclusion Criteria:

          -  A concomitant second solid organ transplant

          -  Immunosuppression not containing tacrolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Z Galante, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidney Transplantation Service - University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabiana Agena, PhD</last_name>
    <phone>+551126618089</phone>
    <email>fabiana.agena@hc.fm.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas - University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Z Galante, PhD</last_name>
      <phone>+551126618089</phone>
      <email>nelson.galante@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Fabiana Agena, PhD</last_name>
      <phone>+551126618089</phone>
      <email>fabiana.agena@hc.fm.usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Romano P, da Luz Fernandes M, de Almeida Rezende Ebner P, Duarte de Oliveira N, Mitsue Okuda L, Agena F, Mendes ME, Massakazu Sumita N, Coelho V, David-Neto E, Zocoler Galante N. UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes. J Pharm Biomed Anal. 2018 Apr 15;152:306-314. doi: 10.1016/j.jpba.2018.01.002. Epub 2018 Jan 5.</citation>
    <PMID>29471254</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>T Lymphocytes</keyword>
  <keyword>B lymphocytes</keyword>
  <keyword>Monitoring, Immunologic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

